356 related articles for article (PubMed ID: 30508425)
1. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
Yebyo HG; Aschmann HE; Puhan MA
Ann Intern Med; 2019 Jan; 170(1):1-10. PubMed ID: 30508425
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
3. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.
Yebyo HG; Zappacosta S; Aschmann HE; Haile SR; Puhan MA
BMC Cardiovasc Disord; 2020 Sep; 20(1):418. PubMed ID: 32942999
[TBL] [Abstract][Full Text] [Related]
4. Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
Zhou Z; Curtis AJ; Ernst ME; Ryan J; Zoungas S; Wolfe R; McNeil JJ; Murray AM; Reid CM; Chowdhury EK; Woods RL; Tonkin AM; Nelson MR
Eur J Clin Pharmacol; 2022 Mar; 78(3):467-476. PubMed ID: 34698889
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
7. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia.
Demoz GT; Wahdey S; Kasahun GG; Hagazy K; Kinfe DG; Tasew H; Bahrey D; Niriayo YL
BMC Res Notes; 2019 Jul; 12(1):386. PubMed ID: 31288848
[TBL] [Abstract][Full Text] [Related]
8. A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Mesgarpour B; Gouya G; Herkner H; Reichardt B; Wolzt M
Lipids Health Dis; 2015 Oct; 14():131. PubMed ID: 26497728
[TBL] [Abstract][Full Text] [Related]
9. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
; Mangione CM; Barry MJ; Nicholson WK; Cabana M; Chelmow D; Coker TR; Davis EM; Donahue KE; Jaén CR; Kubik M; Li L; Ogedegbe G; Pbert L; Ruiz JM; Stevermer J; Wong JB
JAMA; 2022 Aug; 328(8):746-753. PubMed ID: 35997723
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
[TBL] [Abstract][Full Text] [Related]
12. Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Kim J; Kim HS; Yang W; Lee JW; Kang HT
Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32872631
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
[TBL] [Abstract][Full Text] [Related]
14. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling.
Perera R; McFadden E; McLellan J; Lung T; Clarke P; Pérez T; Fanshawe T; Dalton A; Farmer A; Glasziou P; Takahashi O; Stevens J; Irwig L; Hirst J; Stevens S; Leslie A; Ohde S; Deshpande G; Urayama K; Shine B; Stevens R
Health Technol Assess; 2015 Dec; 19(100):1-401, vii-viii. PubMed ID: 26680162
[TBL] [Abstract][Full Text] [Related]
15. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
16. Optimizing statin therapy for primary prevention of cardiovascular disease in type 2 diabetes mellitus patients
Yu JM; Chen WM; Shia BC; Wu SY
Diab Vasc Dis Res; 2023; 20(6):14791641231214507. PubMed ID: 37933122
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG
J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over.
Kwak A; Kim JH; Choi CU; Kim IW; Oh JM; Kim K
Int J Clin Pharm; 2019 Apr; 41(2):460-469. PubMed ID: 30864086
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
